Optiscan Hits Every Milestone With Mayo Clinic and Eyes Robotic Surgery Trials
Two years in, Optiscan and Mayo Clinic reach every milestone in robotic imaging collaboration
Optiscan Imaging Limited (ASX: OIL) has reached the two-year milestone of its Know-How Agreement with Mayo Clinic, with all key engineering milestones and development objectives completed as of 1 June 2026. The Agreement has been extended to 12 August 2026, providing a three-month window for strategic, clinical and commercial planning ahead of anticipated preclinical testing. The collaboration is entering a new phase, with the technical groundwork now firmly in place.
When big ASX news breaks, our subscribers know first
From concept to robotic-ready: what two years of engineering delivered
Over the two-year period, Optiscan and Mayo Clinic worked through a structured development programme spanning the full engineering lifecycle. Major milestones completed under the Agreement include:
- Concept development
- Feasibility assessments
- System requirements reviews
- Prototype development
- Integration testing
- Workflow assessment with Mayo Clinic surgeons for robotic-assisted breast surgery
- Compatibility work demonstrating Picture-in-Picture protocol integration into existing surgeon interfaces
Why flexibility across platforms matters
A deliberate design objective throughout the collaboration has been to avoid single-vendor lock-in. The imaging platform has been built to support potential integration across multiple robotic platforms, rather than being tied to any one vendor ecosystem. This flexibility positions the technology for broader commercial applicability as the robotic surgery market continues to expand.
Next steps include planning further preclinical testing and clinical protocol development, with robotic-assisted breast procedures identified as the first candidate application. These activities will sit outside the current Agreement and remain subject to standard ethics and clinical study approvals.
Understanding endomicroscopic imaging in robotic surgery — and why it changes the equation
Confocal endomicroscopic imaging is a technology that captures real-time, high-resolution images of tissue at the cellular level during surgery, without the need to remove tissue for laboratory analysis. In a robotic surgery context, integrating this capability means a surgeon could assess tumour margins at the moment of the procedure rather than waiting for post-operative pathology results.
The practical significance becomes clear when comparing the standard surgical workflow against the potential with Optiscan’s InVue® imaging system:
| Workflow | Step 1 | Step 2 | Outcome |
|---|---|---|---|
| Standard of Care | Lumpectomy surgery | Post-operative pathology analysis | Uncertain margins / **15–25%** reoperation rate |
| With InVue® Imaging | Lumpectomy surgery | Real-time cellular imaging with InVue® | Immediate margin assessment / potentially reduced reoperation risk |
The robotic surgery market opportunity
The commercial context for this collaboration is substantial. Optiscan’s target expansion market is the United States, which accounts for the majority of global robotic surgery revenue, and Mayo Clinic’s profile directly supports that strategy. Key market data from the announcement includes:
- US surgical robotics market value: approximately USD $7–$7.5 billion
- US share of global robotic surgery revenue: over 50–60%
- Market CAGR: approximately 11–13.5%
The next major ASX story will hit our subscribers first
What comes next for Optiscan and Mayo Clinic
The three-month extension to 12 August 2026 is focused on strategic, clinical and commercial planning. This includes preclinical testing preparation and clinical protocol development, with the multi-platform integration flexibility serving as a foundation for scalability across future robotic surgery applications. The collaboration is expected to continue evolving through further development activities aimed at supporting surgical precision, digital pathology workflow integration and intraoperative decision-making.
Voices from the collaboration
Dr Camile Farah, CEO and Managing Director, Optiscan
“If a robotic tool can hold our imaging technology rather than a human hand, it may deliver greater stability and precision at the microscopic level. The milestones delivered under the Agreement bring us closer to combining precision surgery with real-time imaging, and I look forward to updating the market on further outcomes from this relationship.”
Dr Mara Piltin, Surgical Lead, Mayo Clinic
“The progress achieved to date reflects a strong combination of clinical insight and technical development, and we look forward to continuing to evaluate the potential of Optiscan’s technology to support more informed intraoperative decision-making in the future.”
As a commercial-stage medtech company, Optiscan is building a suite of digital pathology and precision surgery solutions, and the Mayo Clinic relationship serves as a strategic anchor for its US expansion. Completing every planned milestone under a two-year agreement with one of the world’s most recognised healthcare institutions reinforces both the credibility and the scalability of its imaging platform.
Don’t Miss the Next Healthcare Breakthrough on the ASX
Big News Blast delivers FREE breaking ASX healthcare and medtech news directly to your inbox within minutes of release, with in-depth analysis included. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.